ASPEN

Evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations over the 52-week treatment period

Targeted Disease(s):
Non-Cystic Fibrosis Bronchiectasis

Purpose of Study:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis

Study Dates:
November 10, 2020 - April 1, 2024

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Insmed Incorporated

ClinicalTrails.gov Identifier:
NCT04594369

Register for Trial

No upcoming events near you